Retatrutide vs Tirzepatide: Triple vs Dual Incretin Agonism
Retatrutide and Tirzepatide are two multi-receptor incretin-class peptides in current metabolic research. Tirzepatide acts at two receptors — GLP-1 and GIP — and has a completed Phase 3 programme (SURPASS, SURMOUNT). Retatrutide adds a third receptor target, glucagon; its Phase 2 results were published in 2023 and Phase 3 trials are ongoing.
The glucagon receptor is the main structural difference. In the literature, glucagon-receptor agonism is linked to energy expenditure and also to hepatic glucose output. Retatrutide was designed to balance these effects through its combined GLP-1 and GIP receptor activity. The Tirzepatide literature is the larger and more replicated body; the Retatrutide literature is newer and covers an additional receptor pathway.
Retatrutide
- Class
- GLP-1 / GIP / glucagon triple agonist
- Half-life
- ~6 days
Tirzepatide
Full entry →- Class
- GLP-1 / GIP dual agonist
- Half-life
- ~5 days
Key differences at a glance
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor target | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual) |
| Class | Tri-incretin agonist | Dual incretin agonist |
| Half-life (reported) | ~6 days | ~5 days |
| Primary readouts in published trials | Body weight and metabolic markers (Phase 2, 2023) | Body weight and HbA1c (SURMOUNT, SURPASS) |
| Adverse events reported in trials | Mainly gastrointestinal; pattern similar to Tirzepatide | Mainly gastrointestinal |
| Research maturity | Phase 2 published (2023); Phase 3 ongoing | Phase 3 complete (SURMOUNT, SURPASS) |
Why the third receptor matters
The Tirzepatide literature established dual GLP-1 + GIP agonism as a pharmacology distinct from GLP-1 mono-agonism; the SURPASS-2 head-to-head trial against Semaglutide is the main reference. In the reported mechanism, GIP-receptor activation modulates adipocyte lipid handling and adds to the insulin-secretory effect of GLP-1.
Glucagon-receptor agonism adds a different mechanism. The glucagon receptor is linked to lipolysis, fatty-acid oxidation and resting metabolic rate, and also to hepatic glucose output. Earlier glucagon-receptor research could not separate the energy-expenditure readouts from glycemic effects. The receptor-activity ratio of Retatrutide — GLP-1 and GIP agonism that counteracts the glucose-output effect of glucagon — is the reason it is studied as a triple agonist.
Published trial data
The Retatrutide Phase 2 trial (Jastreboff et al., 2023, NEJM) randomized 338 adults with obesity to placebo or one of several Retatrutide arms over 48 weeks, with change in body weight as the primary readout.
The Tirzepatide SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) ran for 72 weeks, also with change in body weight as the primary readout. The trial durations differ and no head-to-head trial has been published, so the literature does not support a direct ranking of the two compounds. Phase 3 trials of Retatrutide are ongoing.
When to pick each
Where the Retatrutide literature focuses
- The Retatrutide literature is the relevant body when the question concerns the glucagon-receptor energy-expenditure pathway.
- It also provides triple-agonist data for comparison with dual-agonist reference data.
- It is the newer of the two literatures, based mainly on the 2023 Phase 2 publication and mechanism studies.
Where the Tirzepatide literature focuses
- The Tirzepatide literature is the relevant body when a longer published trial record is required (SURPASS, SURMOUNT; Phase 3 complete).
- It is also the most replicated dual-incretin reference compound.
- It also covers established research areas where Tirzepatide is the usual comparator.
Frequently Asked Questions
Is Retatrutide just a "stronger Tirzepatide"?
No — the two compounds differ structurally. Tirzepatide is a dual GLP-1 / GIP agonist; Retatrutide adds glucagon-receptor agonism as a third pathway. The glucagon component is linked to energy expenditure, a mechanism Tirzepatide does not engage. Without published head-to-head data, the literature does not support a direct ranking.
Why is glucagon agonism studied at all? Glucagon raises blood sugar.
Glucagon-receptor agonism does raise hepatic glucose output, which is one reason earlier glucagon-receptor research stalled. In Retatrutide, simultaneous GLP-1 receptor activity is reported to counteract glucagon-stimulated glucose release. The published data describe energy-expenditure readouts with a controlled glycemic profile.
Is Retatrutide FDA-approved?
No — Retatrutide is in Phase 3 trials and is not approved. Tirzepatide (as Mounjaro / Zepbound) and Semaglutide (as Ozempic / Wegovy) are FDA-approved medicines for diabetes and weight management. LifeSpanSupply supplies Retatrutide strictly as a research reagent for laboratory use, not for human use.
Are the two compounds studied together?
LifeSpanSupply does not provide combination, dosing or administration guidance. The literature studies Retatrutide and Tirzepatide as separate compounds; class comparisons use parallel study arms.
Which has more research literature published?
Tirzepatide has the longer record — the SURPASS programme covered diabetes endpoints across 5 trials, and SURMOUNT covered obesity across 4 trials. The published Retatrutide record so far is the 2023 Phase 2 NEJM paper plus mechanism studies. Phase 3 data will add to it.
Shop Retatrutide
All products →Shop Tirzepatide
All products →Comparison guides summarize research-context differences. All compounds are chemical reagents for laboratory analysis. See our Terms & Conditions.





